Curcumin protects against A53T alpha-synuclein-induced toxicity in a PC12 inducible cell model for Parkinsonism

Pharmacological Research

Volumn 63, Issue 5, 2011, Pages 439-444

  Liu, Zhaohui ^a   Yu, Yi ^b   Li, Xueping ^b,c   Ross, Christopher A ^b   Smith, Wanli W ^a,b  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

Alpha synuclein; Cell toxicity; Curcumin; Parkinson's disease; PC 12 cell

Indexed keywords

ALPHA SYNUCLEIN; CASPASE 3; CASPASE 9; CURCUMIN; CYTOCHROME C; DOXYCYCLINE; REACTIVE OXYGEN METABOLITE;

ANIMAL CELL; ANTIOXIDANT ACTIVITY; ARTICLE; CELL MEMBRANE DEPOLARIZATION; CELL PROTECTION; CELL STRAIN; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVATION; MITOCHONDRIAL MEMBRANE POTENTIAL; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION;

ALPHA-SYNUCLEIN; ANIMALS; ANTIOXIDANTS; CASPASE 3; CASPASE 9; CELL DEATH; CURCUMA; CURCUMIN; CYTOCHROMES C; HUMANS; MITOCHONDRIA; MUTATION; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; PC12 CELLS; RATS; REACTIVE OXYGEN SPECIES;

EID: 79955478926     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2011.01.004     Document Type: Article

References (62)

1. W. Dauer, and S. Przedborski Parkinson's disease mechanisms and models Neuron 39 6 2003 889
2. L.S. Forno Neuropathology of Parkinson's disease J Neuropathol Exp Neurol 55 3 1996 259
3. M.M. Mouradian Recent advances in the genetics and pathogenesis of Parkinson disease Neurology 58 2 2002 179
4. T.M. Dawson, and V.L. Dawson Molecular pathways of neurodegeneration in Parkinson's disease Science 302 5646 2003 819
5. C.A. Ross, and W.W. Smith Gene-environment interactions in Parkinson's disease Parkinsonism Relat Disord 13 Suppl. 3 2007 S309
6. M.H. Polymeropoulos, C. Lavedan, E. Leroy, S.E. Ide, A. Dehejia, and A. Dutra Mutation in the alpha-synuclein gene identified in families with Parkinson's disease Science 276 1 1997 2045
7. R. Kruger, W. Kuhn, T. Muller, D. Woitalla, M. Graeber, and S. Kosel Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease Nat Genet 18 2 1998 106
8. J.J. Zarranz, J. Alegre, J.C. Gomez-Esteban, E. Lezcano, R. Ros, and I. Ampuero The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia Ann Neurol 55 2 2004 164
9. A.B. Singleton, M. Farrer, J. Johnson, A. Singleton, S. Hague, and J. Kachergus Alpha-synuclein locus triplication causes Parkinson's disease Science 302 5646 2003 841 (Pubitemid 37339619)
10. P. Pals, S. Lincoln, J. Manning, M. Heckman, L. Skipper, and M. Hulihan Alpha-synuclein promoter confers susceptibility to Parkinson's disease Ann Neurol 56 4 2004 591
11. M. Farrer, D.M. Maraganore, P. Lockhart, A. Singleton, T.G. Lesnick, and M. de Andrade Alpha-synuclein gene haplotypes are associated with Parkinson's disease Hum Mol Genet 10 17 2001 1847
12. F. Darios, V. Ruiperez, I. Lopez, J. Villanueva, L.M. Gutierrez, and B. Davletov Alpha-synuclein sequesters arachidonic acid to modulate SNARE-mediated exocytosis EMBO Rep 11 7 2010 528 533
13. F. Cheng, G. Vivacqua, and S. Yu The role of alpha-synuclein in neurotransmission and synaptic plasticity J Chem Neuroanat 2010 10.1016/j.jchemneu.2010.12.001
14. D.E. Cabin, K. Shimazu, D. Murphy, N.B. Cole, W. Gottschalk, and K.L. McIlwain Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking alpha-synuclein J Neurosci 22 20 2002 8797
15. P.K. Auluck, G. Caraveo, and S. Lindquist Alpha-synuclein: membrane interactions and toxicity in Parkinson's disease Annu Rev Cell Dev Biol 26 2010 211 233
16. M.K. Lee, W. Stirling, Y. Xu, X. Xu, D. Qui, and A.S. Mandir Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53 - > Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice Proc Natl Acad Sci USA 99 13 2002 8968
17. L. Chen, and M.B. Feany Alpha-synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease Nat Neurosci 8 5 2005 657
18. P.K. Auluck, H.Y. Chan, J.Q. Trojanowski, V.M. Lee, and N.M. Bonini Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease Science 295 5556 2002 865
19. M.B. Feany, and W.W. Bender A Drosophila model of Parkinson's disease Nature 404 6776 2000 394
20. C. Haass, and P.J. Kahle Parkinson's pathology in a fly Nature 404 6776 2000 341
21. W.W. Smith, H. Jiang, Z. Pei, Y. Tanaka, H. Morita, and A. Sawa Endoplasmic reticulum stress and mitochondrial cell death pathways mediate A53T mutant alpha-synuclein-induced toxicity Hum Mol Genet 14 24 2005 3801
22. H. Jiang, Y.C. Wu, M. Nakamura, Y. Liang, Y. Tanaka, and S. Holmes Parkinson's disease genetic mutations increase cell susceptibility to stress: mutant alpha-synuclein enhances H(2)O(2)- and Sin-1-induced cell death Neurobiol Aging 28 11 2006 1709
23. L. Ko, N.D. Mehta, M. Farrer, C. Easson, J. Hussey, and S. Yen Sensitization of neuronal cells to oxidative stress with mutated human alpha-synuclein J Neurochem 75 6 2000 2546
24. A.R. Saha, N.N. Ninkina, D.P. Hanger, B.H. Anderton, A.M. Davies, and V.L. Buchman Induction of neuronal death by alpha-synuclein Eur J Neurosci 12 8 2000 3073
25. L. Petrucelli, C. O'Farrell, P.J. Lockhart, M. Baptista, K. Kehoe, and L. Vink Parkin protects against the toxicity associated with mutant alpha-synuclein: proteasome dysfunction selectively affects catecholaminergic neurons Neuron 19 2002 1007 36(6)
26. J. Xu, S.Y. Kao, F.J. Lee, W. Song, L.W. Jin, and B.A. Yankner Dopamine-dependent neurotoxicity of alpha-synuclein: a mechanism for selective neurodegeneration in Parkinson disease Nat Med 8 6 2002 600
27. N. Ostrerova, L. Petrucelli, M. Farrer, N. Mehta, P. Choi, and J. Hardy Alpha-synuclein shares physical and functional homology with 14-3-3 proteins J Neurosci 19 14 1999 5782
28. S.J. Tabrizi, M. Orth, J.M. Wilkinson, J.W. Taanman, T.T. Warner, and J.M. Cooper Expression of mutant alpha-synuclein causes increased susceptibility to dopamine toxicity Hum Mol Genet 9 18 2000 2683
29. C. Wersinger, and A. Sidhu Differential cytotoxicity of dopamine and H2O2 in a human neuroblastoma divided cell line transfected with alpha-synuclein and its familial Parkinson's disease-linked mutants Neurosci Lett 342 1-2 2003 124
30. M. Lee, D. Hyun, B. Halliwell, and P. Jenner Effect of the overexpression of wild-type or mutant alpha-synuclein on cell susceptibility to insult J Neurochem 76 4 2001 998
31. C.E. Moussa, C. Wersinger, Y. Tomita, and A. Sidhu Differential cytotoxicity of human wild type and mutant alpha-synuclein in human neuroblastoma SH-SY5Y cells in the presence of dopamine Biochemistry 43 18 2004 5539
32. E. Junn, and M.M. Mouradian Human alpha-synuclein over-expression increases intracellular reactive oxygen species levels and susceptibility to dopamine Neurosci Lett 320 3 2002 146
33. G.J. Kelloff, J.A. Crowell, V.E. Steele, R.A. Lubet, W.A. Malone, and C.W. Boone Progress in cancer chemoprevention: development of diet-derived chemopreventive agents J Nutr 130 2S Suppl 2000 467S
34. Y. Tanaka, S. Engelender, S. Igarashi, R.K. Rao, T. Wanner, and R.E. Tanzi Inducible expression of mutant alpha-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis Hum Mol Genet 10 9 2001 919
35. L.J. Hsu, Y. Sagara, A. Arroyo, E. Rockenstein, A. Sisk, and M. Mallory Alpha-synuclein promotes mitochondrial deficit and oxidative stress Am J Pathol 157 2 2000 401
36. L. Stefanis, K.E. Larsen, H.J. Rideout, D. Sulzer, and L.A. Greene Expression of A53T mutant but not wild-type alpha-synuclein in PC12 cells induces alterations of the ubiquitin-dependent degradation system, loss of dopamine release, and autophagic cell death J Neurosci 21 24 2001 9549
37. H. Elkon, J. Don, E. Melamed, I. Ziv, A. Shirvan, and D. Offen Mutant and wild-type alpha-synuclein interact with mitochondrial cytochrome C oxidase J Mol Neurosci 18 3 2002 229
38. B.L. Zhao, X.J. Li, R.G. He, S.J. Cheng, and W.J. Xin Scavenging effect of extracts of green tea and natural antioxidants on active oxygen radicals Cell Biophys 14 2 1989 175
39. S. Martin-Aragon, J.M. Benedi, and A.M. Villar Modifications on antioxidant capacity and lipid peroxidation in mice under fraxetin treatment J Pharm Pharmacol 49 1 1997 49
40. Sreejayan, and M.N. Rao Nitric oxide scavenging by curcuminoids J Pharm Pharmacol 49 1 1997 105
41. G.P. Lim, T. Chu, F. Yang, W. Beech, S.A. Frautschy, and G.M. Cole The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse J Neurosci 21 21 2001 8370
42. R.A. Sharma, S.A. Euden, S.L. Platton, D.N. Cooke, A. Shafayat, and H.R. Hewitt Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance Clin Cancer Res 10 20 2004 6847
43. N Chainani-Wu Safety and anti-inflammatory activity of curcumin: a component of tumeric (Curcuma longa) J Altern Complement Med 9 1 2003 161
44. R.C. Srimal, and B.N. Dhawan Pharmacology of diferuloyl methane (curcumin), a non-steroidal anti-inflammatory agent J Pharm Pharmacol 25 6 1973 447
45. C.H. Hsu, and A.L. Cheng Clinical studies with curcumin Adv Exp Med Biol 595 2007 471
46. V. Zbarsky, K.P. Datla, S. Parkar, D.K. Rai, O.I. Aruoma, and D.T. Dexter Neuroprotective properties of the natural phenolic antioxidants curcumin and naringenin but not quercetin and fisetin in a 6-OHDA model of Parkinson's disease Free Radic Res 39 10 2005 1119
47. J. Wang, X.X. Du, H. Jiang, and J.X. Xie Curcumin attenuates 6-hydroxydopamine-induced cytotoxicity by anti-oxidation and nuclear factor-kappa B modulation in MES23.5 cells Biochem Pharmacol 78 2 2009 178
48. A. Rajeswari Curcumin protects mouse brain from oxidative stress caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Eur Rev Med Pharmacol Sci 10 4 2006 157
49. M.S. Wang, S. Boddapati, S. Emadi, and M.R. Sierks Curcumin reduces alpha-synuclein induced cytotoxicity in Parkinson's disease cell model BMC Neurosci 11 2010 57
50. K.A. Jellinger Cell death mechanisms in neurodegeneration J Cell Mol Med 5 1 2001 1
51. D.S. Albers, and M.F. Beal Mitochondrial dysfunction and oxidative stress in aging and neurodegenerative disease J Neural Transm Suppl 59 2000 133
52. T. Finkel, and N.J. Holbrook Oxidants, oxidative stress and the biology of ageing Nature 408 6809 2000 239
53. D.T. Dexter, C.J. Carter, F.R. Wells, F. Javoy-Agid, Y. Agid, and A. Lees Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease J Neurochem 52 2 1989 381
54. J. Sian, D.T. Dexter, A.J. Lees, S. Daniel, Y. Agid, and F. Javoy-Agid Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia Ann Neurol 36 3 1994 348
55. Z.I. Alam, A. Jenner, S.E. Daniel, A.J. Lees, N. Cairns, and C.D. Marsden Oxidative DNA damage in the parkinsonian brain: an apparent selective increase in 8-hydroxyguanine levels in substantia nigra J Neurochem 69 3 1997 1196
56. D.T. Dexter, P. Jenner, A.H. Schapira, C.D. Marsden The Royal Kings and Queens Parkinson's Disease Research Group Alterations in levels of iron, ferritin, and other trace metals in neurodegenerative diseases affecting the basal ganglia Ann Neurol 32 Suppl. S94 1992
57. K.A. Jellinger, E. Kienzl, G. Rumpelmaier, W. Paulus, P. Riederer, and H. Stachelberger Iron and ferritin in substantia nigra in Parkinson's disease Adv Neurol 60 1993 267
58. J. Lotharius, and P. Brundin Impaired dopamine storage resulting from alpha-synuclein mutations may contribute to the pathogenesis of Parkinson's disease Hum Mol Genet 11 20 2002 2395
59. D.H. Hyun, M. Lee, N. Hattori, S. Kubo, Y. Mizuno, and B. Halliwell Effect of wild-type or mutant Parkin on oxidative damage, nitric oxide, antioxidant defenses, and the proteasome J Biol Chem 277 32 2002 28572
60. J.N. Keller, F.F. Huang, E.R. Dimayuga, and W.F. Maragos Dopamine induces proteasome inhibition in neural PC12 cell line Free Radic Biol Med 29 10 2000 1037
61. B.J. Tabner, S. Turnbull, N.J. Fullwood, M. German, and D. Allsop The production of hydrogen peroxide during early-stage protein aggregation: a common pathological mechanism in different neurodegenerative diseases? Biochem Soc Trans 33 Pt 4 2005 548
62. S. Turnbull, B.J. Tabner, O.M. El Agnaf, S. Moore, Y. Davies, and D. Allsop Alpha-synuclein implicated in Parkinson's disease catalyses the formation of hydrogen peroxide in vitro Free Radic Biol Med 30 10 2001 1163